![[SEN]Naivek, JP Morgan Healthcare Participation… Announcement of anticancer drug research and discussion of major pipelines](https://img.sedaily.com/web/common/sedaily.jpg "[SEN]Naivek, JP Morgan Healthcare Participation… Announcement of anticancer drug research and discussion of major pipelines")
[서울경제TV=김혜영기자]Peptide fusion bio company Naivek (138610)Will discuss the peptide drug delivery platform and its major pipelines at the ‘2021 JPMorgan Healthcare Conference’ with global pharmaceutical companies.
Naivek announced on the 6th that it will participate in the ‘2021 JP Morgan Healthcare Conference’, which will be held online from January 11th to 14th (local time). At this conference, Naivek plans to present the results of a lung cancer inducing orthotopic tumor model study of’K-RAS mutation inhibitor’ among anticancer drugs based on the peptide drug delivery platform’NIPEP-TPP’.
In addition, the company plans to conduct 1:1 corporate partnerships with major pharmaceutical companies on the results of research on oral and injection treatments in various pipelines such as osteoporosis treatment, lung fibrosis treatment, and inflammatory bowel disease treatment.
A Naivek official said, “We plan to conduct follow-up discussions and technical discussions through corporate partnerships with major pharmaceutical companies on Naivec’s drug delivery platform NIPEP-TPP and various peptide-based pipelines.” As there are no temporal and spatial constraints, practical managers of each pipeline can directly participate in the meeting, so more detailed discussions are expected.”
Through this conference, Naivek expects to proceed with additional contracts with global pharmaceutical companies starting from this event by conducting more detailed follow-up discussions with global big pharmaceuticals that have previously discussed./jss1234567@sedaily .com
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >